Anthem Blue Cross Blue Shield of Colorado policies, page 3

Search Anthem Blue Cross Blue Shield of Colorado's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

550 public policies Substrate tracks for Anthem Blue Cross Blue Shield of Colorado, by title.

Anthem Blue Cross Blue Shield of Colorado policies
PolicyDetailsCodesSource
CG-LAB-11 Vitamin D TestingCG-LAB-11 · Commercial3Original policy ↗
CG-LAB-12 Testing for Oral and Esophageal CancerCG-LAB-12 · Commercial4Original policy ↗
CG-LAB-13 Skin Nerve Fiber Density TestingCG-LAB-13 · Commercial2Original policy ↗
CG-LAB-15 Red Blood Cell Folic Acid TestingCG-LAB-15 · Commercial1Original policy ↗
CG-LAB-16 Serum Amylase TestingCG-LAB-16 · Commercial1Original policy ↗
CG-LAB-17 Molecular Gastrointestinal Pathogen Panel (GIPP) Testing for Infectious Diarrhea in the Outpatient SettingCG-LAB-17 · Commercial3Original policy ↗
CG-LAB-19 Laboratory Evaluation of Vitamin B12CG-LAB-19 · Commercial4Original policy ↗
CG-LAB-20 Thyroid TestingCG-LAB-20 · Commercial4Original policy ↗
CG-LAB-21 Serum Iron TestingCG-LAB-21 · Commercial4Original policy ↗
CG-LAB-22 Nucleic Acid Amplification Tests Using Algorithmic Analysis for the Diagnosis of VaginitisCG-LAB-22 · Commercial5Original policy ↗
CG-LAB-24 Outpatient Urine CultureCG-LAB-24 · Commercial2Original policy ↗
CG-LAB-25 Outpatient Glycated Hemoglobin and Protein TestingCG-LAB-25 · Commercial2Original policy ↗
CG-LAB-26 Outpatient Alpha-Fetoprotein TestingCG-LAB-26 · Commercial2Original policy ↗
CG-LAB-27 Human Chorionic Gonadotropin TestingCG-LAB-27 · Commercial1Original policy ↗
CG-LAB-28 Prostate Specific Antigen TestingCG-LAB-28 · Commercial2Original policy ↗
CG-LAB-29 Gamma Glutamyl Transferase TestingCG-LAB-29 · Commercial1Original policy ↗
CG-LAB-30 Outpatient Laboratory-based Blood Glucose TestingCG-LAB-30 · Commercial3Original policy ↗
CG-LAB-32 Cancer Antigen 125 TestingCG-LAB-32 · Commercial1Original policy ↗
CG-LAB-33 Carcinoembryonic Antigen TestingCG-LAB-33 · Commercial2Original policy ↗
CG-LAB-35 Cancer Antigen 19-9 TestingCG-LAB-35 · Commercial1Original policy ↗
CG-MED-02 Esophageal pH MonitoringCG-MED-02 · Commercial3Original policy ↗
CG-MED-08 Home Enteral NutritionCG-MED-08 · Commercial34Original policy ↗
CG-MED-100 Surface Electrical Stimulation Devices for Headache and MigraineCG-MED-100 · Commercial3Original policy ↗
CG-MED-101 Home HospiceCG-MED-101 · Commercial29Original policy ↗
CG-MED-102 Dichoptic Digital Therapy for AmblyopiaCG-MED-102 · Commercial6Original policy ↗
CG-MED-19 Custodial CareCG-MED-19 · Commercial—Original policy ↗
CG-MED-21 Anesthesia Services and Moderate (“Conscious”) SedationCG-MED-21 · Commercial276Original policy ↗
CG-MED-23 Home HealthCG-MED-23 · Commercial128Original policy ↗
CG-MED-24 Electromyography and Nerve Conduction StudiesCG-MED-24 · Commercial21Original policy ↗
CG-MED-26 Neonatal Levels of CareCG-MED-26 · Commercial—Original policy ↗
CG-MED-28 IontophoresisCG-MED-28 · Commercial2Original policy ↗
CG-MED-34 Monitored Anesthesia Care for Gastrointestinal Endoscopic ProceduresCG-MED-34 · Commercial5Original policy ↗
CG-MED-35 Retinal Telescreening SystemsCG-MED-35 · Commercial3Original policy ↗
CG-MED-37 Intensive Programs for Pediatric Feeding DisordersCG-MED-37 · Commercial1Original policy ↗
CG-MED-39 Bone Mineral Density Testing MeasurementCG-MED-39 · Commercial18Original policy ↗
CG-MED-40 External Ambulatory Cardiac MonitorsCG-MED-40 · Commercial17Original policy ↗
CG-MED-41 Moderate to Deep Anesthesia Services for Dental Surgery in the Facility SettingCG-MED-41 · Commercial10Original policy ↗
CG-MED-47 Fundus PhotographyCG-MED-47 · Commercial2Original policy ↗
CG-MED-49 Auditory Brainstem Responses (ABRs) and Evoked Otoacoustic Emissions (OAEs) for Hearing DisordersCG-MED-49 · Commercial7Original policy ↗
CG-MED-50 Visual, Somatosensory and Motor Evoked PotentialsCG-MED-50 · Commercial10Original policy ↗
CG-MED-52 Allergy Immunotherapy (Subcutaneous)CG-MED-52 · Commercial9Original policy ↗
CG-MED-53 Cervical Cancer Screening Using Cytology and Human Papillomavirus TestingCG-MED-53 · Commercial31Original policy ↗
CG-MED-54 StrappingCG-MED-54 · Commercial9Original policy ↗
CG-MED-57 Cardiac Stress Testing with ElectrocardiogramCG-MED-57 · Commercial4Original policy ↗
CG-MED-59 Upper Gastrointestinal Endoscopy in AdultsCG-MED-59 · Commercial22Original policy ↗
CG-MED-62 Resting Electrocardiogram Screening in AdultsCG-MED-62 · Commercial6Original policy ↗
CG-MED-65 Manipulation Under AnesthesiaCG-MED-65 · Commercial6Original policy ↗
CG-MED-66 Cryopreservation of Oocytes or Ovarian TissueCG-MED-66 · Commercial6Original policy ↗
CG-MED-68 Therapeutic ApheresisCG-MED-68 · Commercial12Original policy ↗
CG-MED-69 Inhaled Nitric OxideCG-MED-69 · Commercial—Original policy ↗

Back to Anthem Blue Cross Blue Shield of Colorado · Anthem Blue Cross Blue Shield of Colorado prior authorization CPT list

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.